GO:0032224 positive regulation of synaptic transmission, cholinergic: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032224 describes any process that activates, maintains or increases the frequency, rate or extent of cholinergic synaptic transmission, the neuron-to-neuron communication event that uses acetylcholine as its neurotransmitter.
• The term is a biological_process child of cholinergic synaptic transmission and is defined by its positive effect on acetylcholine-mediated signaling, not by a single molecular mechanism.
• Cholinergic transmission depends on the coordinated action of choline acetyltransferase (ChAT), the vesicular acetylcholine transporter (VAChT/SLC18A3), nicotinic and muscarinic receptors, and acetylcholinesterase.
• Positive regulation can occur presynaptically (increased ACh synthesis, vesicle filling or release) or postsynaptically (receptor sensitization, increased receptor number or downstream excitability).
• Neuromuscular junction development and function provide a classical model for studying positive regulation of cholinergic transmission because nicotinic acetylcholine receptor clustering is essential for efficient synaptic signaling.
• Pharmacological and genetic tools such as physostigmine, nicotinic receptor agonists and VGLUT3 manipulations can modulate cholinergic transmission and are used to probe this GO term in vivo.
Description
GO:0032224, positive regulation of synaptic transmission, cholinergic, is a Gene Ontology biological_process term that captures any process which activates, maintains or increases the frequency, rate or extent of cholinergic synaptic transmission. Cholinergic synaptic transmission is the process of communication from a neuron to another neuron across a synapse using the neurotransmitter acetylcholine. Because acetylcholine is the neurotransmitter, the term is mechanistically tied to the enzymes, transporters, receptors and ion channels that synthesize, package, release, receive and degrade acetylcholine. Researchers study GO:0032224 to understand how the nervous system strengthens cholinergic circuits, how such strengthening is disrupted in disease, and how pharmacological or genetic interventions can restore or enhance cholinergic signaling. The term is deliberately broad: it encompasses presynaptic mechanisms such as increased acetylcholine synthesis or vesicular release, and postsynaptic mechanisms such as increased receptor sensitivity or number. This breadth makes GO:0032224 a useful annotation target for studies that measure functional changes in cholinergic transmission rather than a single molecular event.
positive regulation of synaptic transmission, cholinergic At A Glance
| GO ID | GO:0032224 |
|---|---|
| GO term | positive regulation of synaptic transmission, cholinergic |
| Ontology | biological_process |
| Synonym | activation of synaptic transmission, cholinergic; stimulation of synaptic transmission, cholinergic; up regulation of synaptic transmission, cholinergic; up-regulation of synaptic transmission, cholinergic; upregulation of synaptic transmission, cholinergic |
| Major function | Increases the frequency, rate or extent of acetylcholine-mediated neuron-to-neuron communication |
| Parent term | cholinergic synaptic transmission |
| Regulates | cholinergic synaptic transmission |
| Related neurotransmitter | Acetylcholine |
| Related cellular components | Synapse, neuromuscular junction, synaptic vesicle, postsynaptic membrane |
What Is GO:0032224?
In plain terms, GO:0032224 describes any biological process that makes cholinergic synaptic transmission stronger, faster or more frequent. The official QuickGO definition states: Any process that activates, maintains or increases the frequency, rate or extent of cholinergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter acetylcholine. The term is a biological_process and is synonymous with activation, stimulation, up regulation, up-regulation or upregulation of cholinergic synaptic transmission. It is the positive counterpart of negative regulation of cholinergic synaptic transmission and is distinct from the parent term cholinergic synaptic transmission, which describes the transmission event itself without specifying direction of regulation.
Why Is positive regulation of synaptic transmission, cholinergic Important in Cell Biology?
GO:0032224 matters because cholinergic transmission underlies attention, learning, memory, muscle contraction and autonomic control, and its positive regulation is a major target of therapeutic and experimental intervention. Dysfunction of cholinergic signaling is implicated in cognitive and motor disorders, and tools that enhance cholinergic transmission, such as acetylcholinesterase inhibitors, are used to modulate these circuits. Understanding which genes and processes positively regulate cholinergic transmission helps researchers interpret genetic screens, pharmacological experiments and disease models that measure synaptic strength.
• Provides a standardized annotation for experiments that measure enhanced acetylcholine-mediated synaptic communication.
• Links presynaptic mechanisms such as acetylcholine synthesis and vesicular release to postsynaptic receptor activation.
• Supports research on the neuromuscular junction, where efficient cholinergic transmission is required for muscle contraction.
• Helps interpret pharmacological studies of acetylcholinesterase inhibitors such as physostigmine that modulate cholinergic neurotransmission.
• Connects cholinergic regulation to cortical network activity, including gamma-band oscillations that depend on metabolic and synaptic modulation.
• Enables comparison of nicotinic receptor subtypes, such as non-alpha7 receptors, that mediate cholinergic transmission onto specific neuron types.
• Provides a framework for studying purinergic and other neuromodulators that regulate acetylcholine release.
• Supports investigation of vesicular transporters such as VGLUT3 that influence cholinergic and other transmitter systems.
• Aids interpretation of genetic and pharmacological models of cognitive and motor disorders involving cholinergic circuits.
• Facilitates cross-species annotation of cholinergic synapse strengthening in neuroscience and drug discovery.
What Happens During positive regulation of synaptic transmission, cholinergic?
Presynaptic acetylcholine synthesis and vesicle loading
In simple terms: The neuron makes more acetylcholine and packs it into synaptic vesicles so that more transmitter is ready for release.
Positive regulation of cholinergic transmission can begin presynaptically with increased activity or expression of choline acetyltransferase (ChAT), the enzyme that synthesizes acetylcholine, and with efficient loading of acetylcholine into synaptic vesicles by the vesicular acetylcholine transporter (VAChT/SLC18A3). ChAT has been studied for decades as the defining enzyme of cholinergic neurons, and its activity is a key determinant of the amount of acetylcholine available for release. Any process that increases ChAT activity, acetylcholine synthesis or vesicular filling can therefore contribute to GO:0032224 by raising the presynaptic pool of releasable transmitter.
Presynaptic release and modulation of release probability
In simple terms: The neuron releases more acetylcholine per impulse, or releases it more often, so the signal reaching the next cell is stronger.
Once acetylcholine is loaded into vesicles, positive regulation of cholinergic transmission can occur through increased release probability or increased frequency of release events. Purinergic signaling is one well-documented modulator of acetylcholine release, and purinergic regulation of acetylcholine release has been described in the nervous system. Purinergic neuromodulation more broadly can influence synaptic transmission, providing a mechanism by which extracellular nucleotides and nucleosides tune cholinergic output. These presynaptic mechanisms are central to GO:0032224 because they directly increase the frequency, rate or extent of acetylcholine-mediated communication.
Postsynaptic nicotinic receptor activation
In simple terms: The receiving neuron has more active nicotinic receptors, so it responds more strongly to the acetylcholine that arrives.
At the postsynaptic side, acetylcholine binds to nicotinic acetylcholine receptors, which are ligand-gated ion channels that depolarize the postsynaptic cell. Nicotinic transmission onto layer 6 cortical neurons has been shown to rely on synaptic activation of non-alpha7 receptors, demonstrating that specific nicotinic receptor subtypes mediate cholinergic synaptic responses in defined circuits. Positive regulation of cholinergic transmission can therefore involve increased numbers, sensitivity or synaptic localization of nicotinic receptors, or enhanced coupling of receptor activation to postsynaptic depolarization. This postsynaptic component is an essential part of GO:0032224 because it determines how effectively a given amount of released acetylcholine drives the receiving neuron.
Neuromuscular junction maturation and receptor clustering
In simple terms: At the muscle-nerve connection, the postsynaptic membrane becomes organized so that acetylcholine signals are transmitted reliably.
The neuromuscular junction is a classical cholinergic synapse, and its development requires clustering of nicotinic acetylcholine receptors and maturation of the postsynaptic apparatus. Witzemann reviewed how the neuromuscular junction develops, including the molecular events that concentrate acetylcholine receptors at the postsynaptic membrane and ensure efficient cholinergic transmission. Processes that promote this maturation or stabilize receptor clusters can positively regulate cholinergic synaptic transmission and thus fall under GO:0032224. This makes the neuromuscular junction a valuable model for studying positive regulation of cholinergic transmission in a structurally well-defined synapse.
Pharmacological enhancement of cholinergic signaling
In simple terms: Drugs can boost cholinergic transmission by blocking the enzyme that breaks down acetylcholine or by acting on receptors.
Pharmacological tools can positively regulate cholinergic transmission. Physostigmine, an acetylcholinesterase inhibitor, modulates hippocampal GABAergic neurotransmission via alpha7 nicotinic acetylcholine receptors, illustrating how increasing acetylcholine levels can engage nicotinic receptors and influence network activity. Such pharmacological enhancement is a practical way to study GO:0032224 because it directly increases the availability of acetylcholine at synapses. Metabolic modulation of neuronal gamma-band oscillations also shows that cholinergic and metabolic factors can interact to shape network-level synaptic activity. These examples demonstrate that positive regulation of cholinergic transmission can be achieved by both genetic and pharmacological means.
Integration with other neurotransmitter systems
In simple terms: Cholinergic transmission does not work alone; other transmitters and transporters can change how strongly acetylcholine signals.
Cholinergic transmission is embedded in a network of neuromodulatory systems. VGLUT3, a vesicular glutamate transporter, contributes to the regulation of serotonergic transmission and anxiety, showing that vesicular transporter composition can influence multiple transmitter systems. Purinergic regulation of acetylcholine release further illustrates cross-talk between transmitter systems. Because GO:0032224 is defined by the positive regulation of cholinergic transmission, processes that alter the presynaptic or postsynaptic environment of cholinergic synapses, including interactions with other transmitters, can contribute to this term. This integration is important for understanding how cholinergic signaling is tuned in complex circuits.
Key Genes Involved in GO:0032224 positive regulation of synaptic transmission, cholinergic
The following genes and proteins are experimentally linked to cholinergic synaptic transmission and its positive regulation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CHAT | Synthesizes acetylcholine from choline and acetyl-CoA | Defining enzyme of cholinergic neurons; target for measuring acetylcholine synthesis capacity |
| SLC18A3 (VAChT) | Loads acetylcholine into synaptic vesicles | Determines vesicular acetylcholine content and release; key presynaptic regulator |
| CHRNA7 | Alpha7 nicotinic acetylcholine receptor subunit | Mediates fast cholinergic transmission; modulated by physostigmine in hippocampus |
| CHRNA4 | Alpha4 nicotinic receptor subunit | Forms non-alpha7 nicotinic receptors involved in cortical cholinergic transmission |
| CHRNB2 | Beta2 nicotinic receptor subunit | Partners with alpha4 to form high-affinity nicotinic receptors in cortex |
| ACHE | Acetylcholinesterase, degrades acetylcholine | Inhibition increases acetylcholine availability and enhances cholinergic transmission |
| SLC18A3 (VGLUT3 in other contexts) | Vesicular glutamate transporter 3 | Contributes to regulation of serotonergic transmission and anxiety; influences vesicular transmitter content |
| P2RY1 | Purinergic receptor for ATP/ADP | Purinergic regulation of acetylcholine release; modulates cholinergic output |
| ADORA1 | Adenosine A1 receptor | Purinergic neuromodulation can inhibit or fine-tune acetylcholine release |
| CHRM1 | Muscarinic acetylcholine receptor M1 | Mediates slow cholinergic modulation in cortex and hippocampus |
| CHRM2 | Muscarinic acetylcholine receptor M2 | Presynaptic autoreceptor that can feedback-regulate acetylcholine release |
| AGRN | Agrin, neuromuscular junction organizer | Promotes acetylcholine receptor clustering at the neuromuscular junction |
| LRP4 | LRP4, agrin receptor partner | Participates in neuromuscular junction maturation and receptor clustering |
| MUSK | Muscle-specific kinase | Required for neuromuscular junction formation and acetylcholine receptor clustering |
| RAPSN | Rapsyn, receptor clustering scaffold | Stabilizes nicotinic acetylcholine receptor clusters at the postsynaptic membrane |
| DOK7 | Dok-7, downstream of MuSK | Supports neuromuscular junction formation and cholinergic synapse stability |
| CACNA1A | Voltage-gated calcium channel subunit | Calcium influx triggers acetylcholine release at presynaptic terminals |
How Is positive regulation of synaptic transmission, cholinergic Regulated?
Positive regulation of cholinergic synaptic transmission is itself regulated at multiple levels. Presynaptically, the amount of acetylcholine released depends on ChAT activity, vesicular loading by VAChT, and the probability of vesicle fusion, which can be modulated by purinergic and other G-protein-coupled receptor pathways. Purinergic neuromodulation provides a broad regulatory layer that can either enhance or suppress acetylcholine release depending on the receptor subtype and cellular context. Postsynaptically, the number and sensitivity of nicotinic and muscarinic receptors determine how strongly a given amount of acetylcholine activates the receiving neuron. At the neuromuscular junction, agrin-LRP4-MuSK signaling and rapsyn-dependent receptor clustering regulate the efficiency of cholinergic transmission during development and maintenance. Metabolic state can also influence network-level cholinergic activity, as shown by metabolic modulation of gamma-band oscillations. Together, these mechanisms ensure that GO:0032224 is a dynamically controlled process rather than a fixed property of cholinergic synapses.
positive regulation of synaptic transmission, cholinergic and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CHRNA7 | Cholinergic modulation of hippocampal neurotransmission | Knockout or point-mutation cell model to test alpha7-dependent responses |
| CHAT | Cholinergic synthesis deficits | Knockout or knockdown to reduce acetylcholine synthesis and measure synaptic output |
| SLC18A3 (VAChT) | Vesicular acetylcholine loading defects | Knock-in of tagged VAChT to monitor vesicle filling and release |
| AGRN | Neuromuscular junction maturation disorders | Knockout or point-mutation models to disrupt receptor clustering |
| MUSK | Neuromuscular junction formation defects | Knock-in of disease-associated mutations to study cholinergic synapse stability |
Cholinergic dysfunction in cognitive and neurodegenerative disorders
Cholinergic transmission is central to attention, learning and memory, and its dysfunction is associated with cognitive impairment. Pharmacological enhancement of cholinergic signaling with acetylcholinesterase inhibitors such as physostigmine is used experimentally to modulate hippocampal neurotransmission via alpha7 nicotinic receptors. Because GO:0032224 describes processes that increase cholinergic transmission, it is directly relevant to understanding how boosting cholinergic signaling may compensate for deficits in cholinergic circuits. Metabolic modulation of gamma-band oscillations further links cholinergic activity to network rhythms that support cognitive processing.
Neuromuscular junction disorders
The neuromuscular junction is a prototypical cholinergic synapse, and its development and maintenance require precise regulation of acetylcholine receptor clustering. Disruption of agrin, LRP4, MuSK, rapsyn or Dok-7 signaling can impair neuromuscular junction formation and cholinergic transmission, leading to motor dysfunction. Studying positive regulation of cholinergic transmission at the neuromuscular junction therefore provides insight into diseases that affect motor endplate function.
Neuropsychiatric and anxiety-related circuits
Cholinergic and other neuromodulatory systems interact in circuits underlying anxiety and mood. VGLUT3 contributes to the regulation of serotonergic transmission and anxiety, indicating that vesicular transporter composition can influence behavior. Purinergic regulation of acetylcholine release adds another layer of neuromodulation that can affect cholinergic tone. These interactions suggest that positive regulation of cholinergic transmission may be relevant to neuropsychiatric conditions in which cholinergic and monoaminergic systems are dysregulated.
From positive regulation of synaptic transmission, cholinergic-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ChAT reduce positive regulation of cholinergic transmission? | CHAT knockout or knockdown cell and animal models |
| Does a point mutation in CHRNA7 alter nicotinic receptor function? | Point-mutation knock-in of CHRNA7 to test receptor sensitivity |
| Can tagged VAChT report vesicular acetylcholine content? | Knock-in of fluorescent or affinity tags on SLC18A3 |
| Does overexpression of a candidate gene enhance acetylcholine release? | Overexpression cell models with synaptic release assays |
| Does disruption of agrin-MuSK signaling impair neuromuscular junction cholinergic transmission? | Knockout or point-mutation models of AGRN, LRP4, MUSK or RAPSN |
| Does VGLUT3 manipulation alter cholinergic or serotonergic transmission? | Knockout or overexpression of SLC18A3 in relevant neurons |
How to Study the positive regulation of synaptic transmission, cholinergic Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Synaptic currents and release probability | Measure positive regulation of cholinergic transmission |
| Miniature synaptic current analysis | Spontaneous quantal release | Distinguish presynaptic vs postsynaptic changes |
| Pharmacological perfusion | Effect of drugs on cholinergic signaling | Test acetylcholinesterase inhibitors or receptor agonists |
| CRISPR knockout | Loss-of-function of cholinergic genes | Test requirement of CHAT or SLC18A3 |
| Knock-in tagging | Localization and dynamics of synaptic proteins | Visualize VAChT or receptor trafficking |
| Immunostaining and imaging | Receptor clustering and synapse structure | Study neuromuscular junction maturation |
| Gamma-band oscillation recording | Network-level activity | Link cholinergic and metabolic modulation |
| Purinergic agonist/antagonist assays | Modulation of acetylcholine release | Probe purinergic regulation of cholinergic transmission |
Electrophysiology and synaptic transmission assays
Electrophysiological recordings are the gold standard for measuring cholinergic synaptic transmission. Nicotinic transmission onto layer 6 cortical neurons has been studied by recording synaptic currents and testing dependence on non-alpha7 receptors. Such assays can detect changes in the frequency, rate or extent of cholinergic transmission, directly reporting GO:0032224. Paired recordings, miniature synaptic current analysis and evoked response measurements allow researchers to distinguish presynaptic from postsynaptic mechanisms.
Pharmacological modulation and receptor pharmacology
Pharmacological tools are widely used to probe positive regulation of cholinergic transmission. Physostigmine, an acetylcholinesterase inhibitor, modulates hippocampal GABAergic neurotransmission via alpha7 nicotinic acetylcholine receptors, providing a way to enhance cholinergic tone and measure downstream effects. Purinergic agents can regulate acetylcholine release, allowing dissection of presynaptic modulation. Dose-response and antagonist experiments help identify which receptor subtypes mediate observed effects.
Genetic models and CRISPR editing
Genetic manipulation of cholinergic genes is essential for causal tests of GO:0032224. Knockout of CHAT or SLC18A3 reduces acetylcholine synthesis or vesicular loading, while knock-in of tagged versions allows visualization of vesicle dynamics. Point mutations in nicotinic receptor subunits can test receptor function in synaptic transmission. CRISPR-based editing enables precise introduction of these alleles in cell and animal models, linking specific genes to positive regulation of cholinergic transmission.
Imaging and network activity measurements
Imaging approaches can report cholinergic synapse structure and network activity. Neuromuscular junction maturation and receptor clustering have been studied with imaging of postsynaptic specializations. Metabolic modulation of neuronal gamma-band oscillations can be measured with electrophysiological or imaging methods, linking cholinergic activity to network rhythms. These techniques complement electrophysiology by showing where and when cholinergic transmission is enhanced.
How CRISPR Can Be Used to Study GO:0032224 positive regulation of synaptic transmission, cholinergic
Knockout
CRISPR knockout of genes such as CHAT, SLC18A3 or nicotinic receptor subunits can test whether they are required for positive regulation of cholinergic transmission. Loss of ChAT reduces acetylcholine synthesis, while loss of VAChT impairs vesicular loading, both of which would be expected to decrease cholinergic synaptic strength. Knockout of receptor subunits can reveal which nicotinic receptors mediate cholinergic transmission in a given circuit. These models provide causal evidence for gene function in GO:0032224.
Point Mutation
Point mutations can be introduced into cholinergic genes to model disease-associated variants or to dissect specific residues required for function. For example, point mutations in nicotinic receptor subunits can alter ligand sensitivity or ion conductance, affecting postsynaptic responses to acetylcholine. Such models are valuable for testing whether a specific molecular change enhances or impairs positive regulation of cholinergic transmission.
Knock-in
Knock-in of tags or reporter sequences allows visualization and quantification of cholinergic proteins in their endogenous context. Tagging VAChT or ChAT can reveal vesicle loading and enzyme localization, providing mechanistic insight into presynaptic regulation. Knock-in of disease-relevant mutations in neuromuscular junction genes such as AGRN or MUSK can model cholinergic synapse defects. These approaches link specific alleles to functional changes in cholinergic transmission.
Overexpression
Overexpression of candidate genes can test whether increased protein levels are sufficient to enhance cholinergic transmission. For example, overexpression of ChAT or VAChT might increase acetylcholine synthesis or vesicular content, potentially strengthening cholinergic synapses. Overexpression of purinergic receptors or other modulators could also alter acetylcholine release. Such gain-of-function models complement knockout studies and help define sufficiency for GO:0032224.
How EDITGENE Supports positive regulation of synaptic transmission, cholinergic Research
Researchers studying positive regulation of synaptic transmission, cholinergic-related genes often need to determine whether a candidate gene is causally involved in enhancing acetylcholine-mediated communication. EDITGENE provides CRISPR-based cell models and screening services to test these hypotheses with precision.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of synaptic transmission, cholinergic research.
Frequently Asked Questions About positive regulation of synaptic transmission, cholinergic
What is GO:0032224?
GO:0032224 is the Gene Ontology term for positive regulation of synaptic transmission, cholinergic, defined as any process that activates, maintains or increases the frequency, rate or extent of cholinergic synaptic transmission.
What is positive regulation of synaptic transmission, cholinergic?
It is the biological process that enhances acetylcholine-mediated communication between neurons, either presynaptically or postsynaptically.
What genes are involved in positive regulation of synaptic transmission, cholinergic?
Key genes include CHAT, SLC18A3 (VAChT), CHRNA7, CHRNA4, CHRNB2, ACHE and neuromuscular junction genes such as AGRN, LRP4, MUSK and RAPSN.
How is cholinergic synaptic transmission regulated?
It is regulated by acetylcholine synthesis, vesicular loading, release probability, receptor number and sensitivity, and by neuromodulators such as purinergic agents.
What is the role of CHAT in cholinergic transmission?
CHAT synthesizes acetylcholine and is the defining enzyme of cholinergic neurons, so its activity directly affects the amount of transmitter available for release.
What is the role of VAChT in cholinergic transmission?
VAChT loads acetylcholine into synaptic vesicles, determining how much transmitter can be released per impulse.
How do nicotinic receptors contribute to cholinergic transmission?
Nicotinic receptors are ligand-gated ion channels that depolarize the postsynaptic cell in response to acetylcholine; non-alpha7 receptors mediate transmission onto layer 6 cortical neurons.
Can drugs enhance cholinergic transmission?
Yes, acetylcholinesterase inhibitors such as physostigmine increase acetylcholine availability and can modulate hippocampal neurotransmission via alpha7 nicotinic receptors.
What diseases involve cholinergic synaptic dysfunction?
Cognitive disorders, neuromuscular junction disorders and neuropsychiatric conditions have been linked to altered cholinergic transmission.
How can CRISPR help study GO:0032224?
CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of genes that regulate cholinergic synaptic transmission.
Conclusion
GO:0032224, positive regulation of synaptic transmission, cholinergic, provides a standardized way to annotate processes that enhance acetylcholine-mediated communication between neurons. It encompasses presynaptic mechanisms such as acetylcholine synthesis and vesicular release, postsynaptic mechanisms such as nicotinic receptor activation, and modulatory influences from purinergic and other systems. Understanding this term is important for neuroscience, neuromuscular biology and drug discovery, and CRISPR-based models offer powerful tools to test causal roles of specific genes. By combining precise gene editing with functional assays, researchers can dissect how cholinergic transmission is positively regulated in health and disease.
References
- 1. Witzemann V. 2006. Development of the neuromuscular junction.. Cell Tissue Res 326(2):263-71 PMID: 16819627
- 2. Karkos J. 1990. [Purinergic neuromodulation].. Fortschr Neurol Psychiatr 58(1):33-42 PMID: 2155163
- 3. Hay YA et al.. 2016. Nicotinic Transmission onto Layer 6 Cortical Neurons Relies on Synaptic Activation of Non-α7 Receptors.. Cereb Cortex 26(6):2549-2562 PMID: 25934969
- 4. Ribeiro JA et al.. 1996. Purinergic regulation of acetylcholine release.. Prog Brain Res 109:231-41 PMID: 9009712
- 5. Hernández-Abrego A et al.. 2026. Physostigmine modulates hippocampal GABAergic neurotransmission via α7 nicotinic acetylcholine receptors.. Neuropharmacology 283:110736 PMID: 41326234
- 6. Vodovozov W et al.. 2018. Metabolic modulation of neuronal gamma-band oscillations.. Pflugers Arch 470(9):1377-1389 PMID: 29808353
- 7. Amilhon B et al.. 2010. VGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety.. J Neurosci 30(6):2198-210 PMID: 20147547
- 8. Wu D et al.. 1994. Choline acetyltransferase: celebrating its fiftieth year.. J Neurochem 62(5):1653-63 PMID: 8158117
